Patented products
Patents are a prerequisite to preserving Iconovo’s position as an established player for inhalation products. New concepts and methods are continuously patented. The company has designed or is in the process of designing four different inhaler platforms that are protected by nine patent families. Patents are already approved for the finally designed inhaler platforms, namely ICOone, ICOcap and ICOres.
The table lists the approved patents. These patents have also been filed internationally.
Platform | Approved in | Pending | Year of expiry |
---|---|---|---|
1 ICOres™ | EP,JP | 2035 | |
2 ICOres™ | EP | China | 2034 |
3 ICOres™ | SE | 2034 | |
4 ICOres™ | EP, China, US | Ind, JP | 2036 |
5 ICOres™ | EP, US | 2036 | |
6 ICOres™ | EP | CA | 2038 |
7 ICOres™ | PCT | 2039 | |
8 ICOres™ | SE | 2039 | |
9 ICOone™ | SE | 2033 | |
10 ICOone™ | EP | China, Ind, JP, US | 2035 |
11 ICOone™ | EP, China; Ind, JP, US | 2038 | |
12 ICOcap™ | EP | 2036 | |
13 ICOpre™ | SE | 2040 | |
14 ICOpre™ | SE | 2040 |
Possessing a unique combination
of engineering and pharma expertise, Iconovo can provide the optimal combination of customized inhalers and tailored formulations.
ICONOVO AB
VISITING ADDRESS
Ideon, Delta 6 Lund
Ideongatan 3B
POSTAL ADDRESS
Iconovo AB
Ideongatan 3A-B
SE-223 70 LUND
Sweden
CONTACT
Phone: +46 46 275 67 77
VP Business Development
Roger Lassing
Mail: roger.lassing@iconovo.se
CEO
Johan Wäborg
Mail: johan.waborg@iconovo.se